Fully Human Antibody Development Platform—NeoMab Bio
Officially Opens in Suzhou
SUZHOU, China, May 22, 2024
/PRNewswire/ -- On May 22,
2024, NeoMab Biotechnology (Suzhou) Co., Ltd. celebrated its
grand opening in Suzhou Industrial Park (BioBAY). This marks a
significant milestone that will further enhance the high-quality
development of Suzhou's biopharmaceutical innovation cluster. The
ceremony was attended by government representatives, investors, and
various industry experts and enterprise representatives from the
biopharmaceutical field, all witnessing this important event
together.
Relying on its strong scientific research and talent
capabilities and the vigorous support from the Suzhou Industrial
Park government, GemPharmatech Co., Ltd. established a
wholly-owned subsidiary, NeoMab Biotechnology (Suzhou) Co.,
Ltd., focusing on the development of fully human antibodies based
on the NeoMab™ transgenic mouse platform. The company has also set
up the NeoMab™ fully human antibody discovery platform.
NeoMab Bio aims to provide more flexible and cost-effective
solutions for research institutions, biotechnology companies, and
pharmaceutical enterprises dedicated to antibody development.
According to Dr. Xiang
Gao, President of GemPharmatech: "The application
of antibody fully humanized mice in antibody development and
screening is a significant catalyst for the development of antibody
drugs, providing a solid foundation for nurturing the future
biopharmaceutical industry. In order to achieve a competitive
position in the domestic antibody drug development field that can
be comparable to leading countries in the world, we will spare no
effort."
According to Michael Yin, Chairman of BioBAY: "I
sincerely hope that NeoMab Bio can take this as a new starting
point, further deepening its roots in the Suzhou Industrial Park,
accelerating the development of the biopharmaceutical industry in
the park, and contributing to the advancement of antibody drug
research in our country."
According to Dr. Jing Zhao, CEO
of GemPharmatech: "We are grateful for the strong
support and care provided by the Suzhou Municipal People's
Government, Suzhou Industrial Park Government, and government
officials at all levels for NeoMab Bio. Throughout our development,
we have consistently felt the selfless support and assistance
provided by the government. We thank all our partners and customers
for their trust and support. The success of the antibody discovery
platform is a result of your collective efforts and sincere
cooperation. In the future, we will continue to uphold the concept
of win-win cooperation, work hand in hand with everyone, and
jointly promote the development and application of antibody
technology, contributing more to the cause of human health."
As an important member of GemPharmatech, NeoMab Bio believes
that with the favorable environment created by the Suzhou
Industrial Park Government, it will continue to uphold the spirit
and philosophy of "Models to defy the impossible" continuously
enhance its scientific research capabilities, provide
higher-quality services to biopharmaceutical enterprises, and
become a strong force in the development of the industry.
About GemPharmatech
GemPharmatech Co., Ltd, founded in 2017, is a high-tech
enterprise specializing in the research, production, sales, and
related technical services of experimental animal mouse models. It
is a member of the Asian Mouse Mutant and Resource Alliance and a
co-construction unit of the National Engineering Mouse Resource
Library certified by the Ministry of Science and Technology. Based
on the strategy of creating experimental animals and genetic
engineering modification technology, the company provides customers
with commercially available mouse models with independent
intellectual property rights, as well as one-stop services such as
customized model breeding and functional efficacy analysis, meeting
the needs of customers in the fields of basic research and new drug
development, such as gene function cognition, disease mechanism
analysis, drug target discovery, and drug efficacy screening and
verification.
About NeoMab Bio
NeoMab Bio is a wholly-owned subsidiary of GemPharmatech Co.,
Ltd., located in the Suzhou BioBay. NeoMab Bio is committed to
becoming a trusted partner in the field of antibody drug discovery
by providing efficient and convenient antibody drug discovery
service. NeoMab Bio has an experienced team of scientists and
technical personnel dedicated to developing cutting-edge technology
and innovative solutions. The company has advanced laboratories and
equipment, providing a full range of antibody drug discovery
services, including target validation, antibody generation and
screening, and preclinical study. In addition, NeoMab Bio offers
flexible business cooperation models, including NeoMab™ mouse usage
authorization, fully human antibody development services, and
potential molecular license-out.
View original
content:https://www.prnewswire.com/news-releases/aiming-for-new-quality-productivity-aiding-in-reaching-the-summit-of-global-innovative-pharmaceuticals-302152993.html
SOURCE GemPharmatech Co., Ltd.